Cargando…

Targeting the ALK–CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex

Poly(ADP-ribose) polymerase (PARP) inhibitors have demonstrated promising clinical activity in multiple cancers. However, resistance to PARP inhibitors remains a substantial clinical challenge. In the present study, we report that anaplastic lymphoma kinase (ALK) directly phosphorylates CDK9 at tyro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chu, Yu-Yi, Chen, Mei-Kuang, Wei, Yongkun, Lee, Heng-Huan, Xia, Weiya, Wang, Ying-Nai, Yam, Clinton, Hsu, Jennifer L., Wang, Hung-Ling, Chang, Wei-Chao, Yamaguchi, Hirohito, Jiang, Zhou, Liu, Chunxiao, Li, Ching-Fei, Nie, Lei, Chan, Li-Chuan, Gao, Yuan, Wang, Shao-Chun, Liu, Jinsong, Westin, Shannon N., Lee, Sanghoon, Sood, Anil K., Yang, Liuqing, Hortobagyi, Gabriel N., Yu, Dihua, Hung, Mien-Chie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9586872/ https://www.ncbi.nlm.nih.gov/pubmed/36253486 http://dx.doi.org/10.1038/s43018-022-00438-2

Ejemplares similares

Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors
por: Chu, Yu-Yi, et al.
Publicado: (2022)

CDK4/6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: Are we at the finish line?
por: Yam, Clinton, et al.
Publicado: (2018)

An optimized protocol for PD-L1 pathological assessment with patient sample deglycosylation to improve correlation with therapeutic response
por: Wang, Ying-Nai, et al.
Publicado: (2022)

Ribonuclease 1 Enhances Antitumor Immunity against Breast Cancer by Boosting T cell Activation
por: Wang, Ying-Nai, et al.
Publicado: (2023)

EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer
por: Yamaguchi, Hirohito, et al.
Publicado: (2017)

Regulation and Role of EZH2 in Cancer
por: Yamaguchi, Hirohito, et al.
Publicado: (2014)

Tyr1 phosphorylation promotes phosphorylation of Ser2 on the C-terminal domain of eukaryotic RNA polymerase II by P-TEFb
por: Mayfield, Joshua E, et al.
Publicado: (2019)

Prospects of the potential strategies to improve the efficacy of anti‐PD‐1/PD‐L1 therapy
por: Yamaguchi, Hirohito, et al.
Publicado: (2022)

Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer
por: Qiu, Yufan, et al.
Publicado: (2021)

The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis
por: Wang, Ying-Nai, et al.
Publicado: (2020)

Regulation of Ubiquitination-Mediated Protein Degradation by Survival Kinases in Cancer
por: Yamaguchi, Hirohito, et al.
Publicado: (2012)

P-TEFb- the final frontier
por: Kohoutek, Jiri
Publicado: (2009)

P‐TEFb goes viral
por: Zaborowska, Justyna, et al.
Publicado: (2015)

Cancer Cell Metabolism Bolsters Immunotherapy Resistance by Promoting an Immunosuppressive Tumor Microenvironment
por: Jiang, Zhou, et al.
Publicado: (2020)

Megakaryocytic irreversible P-TEFb activation
por: Elagib, Kamaleldin E, et al.
Publicado: (2014)

Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors
por: Du, Yi, et al.
Publicado: (2016)

Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer
por: Cha, Jong-Ho, et al.
Publicado: (2022)

Deubiquitination and stabilization of PTEN by USP13
por: Zhang, Jinsong, et al.
Publicado: (2013)

Inhibition of Type I Insulin-Like Growth Factor Receptor Signaling Attenuates the Development of Breast Cancer Brain Metastasis
por: Saldana, Sandra M., et al.
Publicado: (2013)

P-TEFb as A Promising Therapeutic Target
por: Fujinaga, Koh
Publicado: (2020)

Nuclear functions and subcellular trafficking mechanisms of the epidermal growth factor receptor family
por: Wang, Ying-Nai, et al.
Publicado: (2012)

Destabilization of macrophage migration inhibitory factor by 4‐IPP reduces NF‐κB/P‐TEFb complex‐mediated c‐Myb transcription to suppress osteosarcoma tumourigenesis
por: Zheng, Lin, et al.
Publicado: (2022)

Manipulation of P-TEFb control machinery by HIV: recruitment of P-TEFb from the large form by Tat and binding of HEXIM1 to TAR
por: Sedore, Stanley C., et al.
Publicado: (2007)

Herbal Compounds Dauricine and Isoliensinine Impede SARS-CoV-2 Viral Entry
por: Dabrell, Shaneek Natoya, et al.
Publicado: (2023)

Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation
por: Lee, Heng-Huan, et al.
Publicado: (2021)

Case Report: A Novel Non-Reciprocal ALK Fusion: ALK-GCA and EML4-ALK Were Identified in Lung Adenocarcinoma, Which May Respond to Alectinib Adjuvant-Targeted Therapy
por: Zhai, Xiaoqian, et al.
Publicado: (2022)

A case of large-cell neuroendocrine carcinoma harboring rare ALK fusion with initial response to the ALK inhibitor crizotinib and acquired F1174L mutation after resistance
por: Wang, Ye, et al.
Publicado: (2019)

Pharmacologic targeting of the P-TEFb complex as a therapeutic strategy for chronic myeloid leukemia
por: Qing, Yingjie, et al.
Publicado: (2021)

PKC phosphorylates HEXIM1 and regulates P-TEFb activity
por: Fujinaga, Koh, et al.
Publicado: (2012)

P-TEFb is degraded by Siah1/2 in quiescent cells
por: Huang, Fang, et al.
Publicado: (2022)

Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex
por: Biglione, Sebastian, et al.
Publicado: (2007)

A novel ligand-receptor relationship between families of ribonucleases and receptor tyrosine kinases
por: Wang, Ying-Nai, et al.
Publicado: (2018)

Natural tannins as anti-SARS-CoV-2 compounds
por: Wang, Shao-Chun, et al.
Publicado: (2022)

DAB2IP suppresses invadopodia formation through destabilizing ALK by interacting with USP10 in breast cancer
por: Huang, Qingwen, et al.
Publicado: (2023)

Novel NLRC4‐ALK and EML4‐ALK double fusion mutations in a lung adenocarcinoma patient: A case report
por: Wu, Xueqian, et al.
Publicado: (2020)

Beyond NF-κB activation: nuclear functions of IκB kinase α
por: Huang, Wei-Chien, et al.
Publicado: (2013)

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
por: Li, Chia-Wei, et al.
Publicado: (2016)

Classical ALK G1202R resistance mutation was identified in a lung adenocarcinoma patient with rare LOC388942-ALK fusion after sequential treatment with ALK-TKIs and anlotinib: a case report
por: Zhai, Xiaoqian, et al.
Publicado: (2022)

Crystal structure of HIV-1 Tat complexed with human P-TEFb
por: Tahirov, Tahir H., et al.
Publicado: (2010)

Role of Noncoding RNAs in the Regulation of P-TEFb Availability and Enzymatic Activity
por: Napolitano, Giuliana, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ht4rbp3a8s6edjtj3fe7ig8ia9